Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer.

NPJ Breast Cancer · 2021 · PMC8163849 · PMID 34050190

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

showed a trendp = 0.059so close (0.05 < p ≤ 0.1)

1F , heparanase was associated with worse DFS (log-rank test p = 0.004; hazard ratio: 2.03; 95% CI 1.24–3.33) and showed a trend towards worse OS (log-rank test p = 0.059; hazard ratio: 1.84; 95% CI 0.97–3.50).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.